Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093325 | 0.82 | CA2 (0.56) | ALDH1A1LMNASMN1; SMN2THRBL3MBTL1 | |
| SCHEMBL18553725 | 0.81 | LMNA (0.69) | ALDH1A1LMNASMN1; SMN2THRBL3MBTL1 | |
| SCHEMBL23093329 | 0.81 | LMNA (0.69) | ALDH1A1LMNASMN1; SMN2THRBL3MBTL1 | |
| SCHEMBL8423976 | 0.81 | ALDH1A1 (0.51) | ALDH1A1LMNASMN1; SMN2THRBL3MBTL1 | |
| SCHEMBL7498033 | 0.80 | CA2 (0.83) | ALDH1A1LMNASMN1; SMN2CA2CA1 | |
| SCHEMBL23093348 | 0.79 | PKLR (0.61) | ALDH1A1LMNASMN1; SMN2CA2CA1 | |
| SCHEMBL22516003 | 0.78 | ALDH1A1 (0.74) | ALDH1A1LMNASMN1; SMN2THRBL3MBTL1 | |
| SCHEMBL23787100 | 0.77 | PKM (0.66) | ALDH1A1LMNASMN1; SMN2KDM4EKMT2A | |
| SCHEMBL23093497 | 0.75 | CA2 (0.61) | ALDH1A1LMNASMN1; SMN2CA2CA1 | |
| SCHEMBL7577204 | 0.75 | CA2 (0.66) | ALDH1A1LMNASMN1; SMN2POLBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | UNIV EMORY (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2021050721-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | EMORY UNIVERSITY (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059658-A1 | QUINOLINE DERIVATIVES AND USES IN MANAGING CANCER | MDM2, TP53, RECQL | ALDH1A1 1022/4885LMNA 1657/4885SMN1; SMN2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.